The study of myeloid leukemia induced by slow transforming murine leukemia viruses (MuLV) in the laboratory mouse has led to discovery of many important genes with critical roles in regulating the growth, death, lineage determination and development of hematopoietic precursor cells. This review provides an overview of the susceptible strains and virus isolates that cause acute myeloid leukemia (AML) in mice. In addition, newer methodologies, involving the use of the polymerase chain reaction, that have been used to identify cancer genes mutated by proviral insertion in mouse models, will be discussed. As cancer is a multi-gene disease, a system in which pairs of oncogenic mutations are classified as redundant, neutral or synergistic is described. The potential to combine MuLV mutagenesis with recent advances in mouse transgenesis in order to model specific forms of myeloid leukemia or genetic pathways common in human AML will be discussed. Finally, a general strategy for maximizing these genetically rich models to foster a better understanding of AML physiology and developing therapies is proposed. Leukemia (2000) 14, 1174-1184. Keywords: acute myeloid leukemia; mouse; MuLV; molecular cloning
MuLV-induced AML
Several excellent reviews have been published which describe MuLV-induced leukemia [1] [2] [3] [4] [5] [6] or mouse models of AML. [7] [8] [9] Therefore, only a brief summary of the diversity of mouse strains and virus combinations that result in AML is in order. For the purposes of this review, acute erythrocytic and megakaryocytic leukemias are not considered; instead, the focus is on AML representing earlier progenitors or neutrophil and monocyte/macrophage progenitors. It had been shown that various MuLV could induce non-B, non-T cell leukemia in susceptible mice by the early 1980s. [10] [11] [12] [13] [14] [15] It was shown that these leukemias consisted of cells in various myeloid lineages and stages of maturation. Criteria for classification of myeloid leukemia in mice have included lack of B or T cell antigen receptor gene rearrangements, 16 ,17 myeloid esterase staining, 11 cell and nuclear morphology, 13, 18 induction of differentiation to mature myeloid cell types and expression of lineage-specific genes or cell surface markers. 15, 19 A system of classification of human AML into subtypes, called the French-American-British (FAB) system, 20, 21 has proved useful in distinguishing AML according to many important clinical phenotypes such as prognosis, response to various therapies, development of intercurrent problems, and Table 1 ). The FAB subclassifications are based primarily on morphological appearance, myeloid esterase staining, and expression of cell surface markers. To some extent, specific genetic changes, such as chromosomal translocations, tend to cluster within a FAB subtype of AML, indicating that these definitions do indeed reflect basic genetic differences between subtypes that probably dictate their behavior. A good example of this is the strong correlation between translocations involving the retinoic acid receptor alpha (RARA) gene and AML subtype M3, acute promyelocytic leukemia. 22, 23 A well described and documented system of classification, similar to the FAB classification, is lacking for mouse AML. For some models, there is considerable heterogeneity in the type of leukemia that develops after MuLV infection. For instance, infection of NIH Swiss mice with SRS-19-6 MuLV results in erythroid, T cell, B cell and myeloblastic leukemia. 24 Clearly, the potential exists for varying subtypes of AML to develop within one model. Therefore, variation may exist not only between, but also within models of MuLV-induced AML. At least one review has made an attempt at correlating the phenotype of the AML that develop in many different mouse models with human AML subtypes as defined by the FAB system of classification. 7 Most of these judgments are based on limited analyses reported in older journal articles. A summary of the MuLV and strain combinations that lead to a significant number of AML is shown in Table 2 . Included are the human FAB subtypes most like these murine models of AML based on their published descriptions and a review by Perkins. 7 Acute promyelocytic leukemia (AML M3) may be very rare in MuLVinfected mice. One report describes the establishment of APLlike cell lines from AML developing in Rauscher MuLVinfected mice, 19 but otherwise no description of MuLVinduced AML M3 exists in mice. This is not because AML M3 cannot develop in mice, since several transgenic mouse lines have been made which develop this form of leukemia. [25] [26] [27] Most models of MuLV-induced AML seem to be analogous to AML M1, M2, or M4 in humans. 7 Little can be said at this point about whether each of the models listed in Table 2 develop one or all three of these subtypes. Spontaneous AML in mice has been classified into two groups based on cell morphology, disease presentation and ultrastructure analyzed using electron microscopy: juvenile granulocytic leukemia or mature granulocytic leukemia. 28 It is clear that a more sophisticated and systematic evaluation of AML phenotypes in mice is in order. A detailed examination of AML developing in BHX-2 mice indicates great differences in positivity for myeloid surface markers and esterase staining (Ref. 29 , DAL unpublished observations). It would appear that, consistent with differences in the phenotypes of MuLV-induced AMLs, the genes that are recurrently mutated in these models also differ markedly. For example, while 100% of AKXD-23 AML have proviral insertions activating the Evi1 proto-oncogene, 30 no Evi1 insertions have been observed in BXH-2 strain AML. 31 MuLV induce disease in susceptible hosts by multiple mechanisms. It is thought that early events in oncogenesis may include, in addition to activation of cellular proto-oncogenes, the enhanced proliferation of specific cell types. 2, 5 The evidence for this mechanism is mostly restricted to spleen focus-forming virus (SFFV)-induced erythroleukemia, in which an altered envelope gene product causes polyclonal expansion of erythroid progenitors by interacting with the erythropoietin receptor. 32 Similar mechanisms have not been described for other models of MuLV-induced AML. Mink cell focusforming virus (MCF) generation is thought to be critical for the development of many lymphoid malignancies, and of erythroleukemia in mice after MuLV infection. 5, 33 The generation of recombinant MCF occurs by recombination between endogenous xenotropic-like MuLV and ecotropic MuLV. In some cases, this allows superinfection interference, which normally prevents efficient reinfection of cells by MuLV, to be Leukemia overcome. However, MCF are not obligately involved in all MuLV-induced lymphoid malignancies, but instead often merely accelerate disease, and no MCF are generated during the development of leukemia in Moloney-MuLV infected rats. 5 While MCF are known to be generated in some models of MuLV-induced AML, 34, 35 their role has not been evaluated. In summary, little is known about preleukemic events in MuLVinduced AML. However, it can be said that in some models, proviral insertion affecting cellular proto-oncogenes is certainly an early event. For example, Cmyb insertions have been detected early in the disease course for Moloney-MuLVinduced promonocytic leukemia in BALB/c mice. 36 Late events in MuLV-induced AML include the selection of clones of cells harboring non-random proviral insertions in chromosomal locations that affect the expression of nearby cancer genes. Thus, MuLV induce cancer by acting, in part, as insertional mutagens (Figure 1) . By using the sequence of the MuLV as a molecular tag, it has been possible to clone common sites of proviral insertion from these AML, ie MuLV insertional mutagenesis. (a) A provirus may integrate near a proto-oncogene and cause it to be expressed inappropriately or may insert within a tumor suppressor gene and inactivate it. (b) MuLV-induced leukemia is characterized by a preleukemic period during which many millions of infection events occur. Inevitably a rare cell suffers an initiating event, which is followed by a process of tumor progression, during which subclones are selected with increasing malignant potential and which have acquired additional mutations. Eventually a fully malignant tumor spreads and predominates in the animal.
chromosomal sites occupied by a somatically acquired, tumor-specific provirus in multiple, independent tumors. 5 By searching the genomic DNA flanking these common sites of insertion, many different myeloid oncogenes and at least one tumor suppressor gene have been implicated in the development of myeloid leukemia (Table 3 ). This type of analysis has now made it clear that there must be many pathways to myeloid leukemia. Twenty-two different AML genes have now been revealed by the study of MuLV-induced AML (Table 3 ). An examination of Table 3 http://www.ncbi.nlm.nih.gov/CCAP/mitelsum.cgi). Many of the more common balanced chromosomal translocations have been defined at the molecular level and the genes involved are now known. However, a plethora of other balanced and unbalanced chromosomal abnormalities have been described in which the involved genes are not yet known. 37 In fact, many of the recurrent changes in human AML involve the loss or acquisition of chromosomal material, suggesting that changes in the copy number of certain genes may contribute to myeloid leukemia. Several loci have been defined, which show frequent loss of heterozygosity (LOH) for polymorphic markers, cytogenetically evident deletions, and are on chromosomes often showing monosomy. Examples are the 7q22 and 5q31 regions. 38 These regions are likely to contain important tumor suppressor genes for myeloid leukemia.
There may be considerable overlap between the genes mutated in mouse AML models and human AML. In fact, in several cases, the same gene has been implicated in the development of both human and mouse AML. Examples include the NF1 tumor suppressor gene, 29, 39, 40 the HOXA9 oncogene, 41, 42 and the AML1 (Cbfa2) oncogene. 43 At present, most of the common human AML translocations have been molecularly defined. 37, 44 Study of the mouse models of MuLVinduced AML promise to be much more fruitful in the hunt for remaining AML genes than does study of human patient samples. The primary advantage of studying MuLV-induced AML for cancer gene identification is having a sequence tag with which to gain access to the genomic regions of interest. Considerable clinical and experimental evidence exists to suggest that the known fusion oncoproteins produced by translocations in human AML are not sufficient to cause AML. These data include the observation that multiple clonal chromosomal abnormalities are often found in AML 37, 45, 46 and the failure to observe rapid, polyclonal AML in transgenic mice made to express these fusion oncoproteins in vivo. 25, 26, 47 Thus, it has been suggested that secondary genetic events contribute to human AML that are initiated by these more common translocations. 46 Molecular identification of these secondary genetic events may be very difficult using human patient samples alone, especially if many of the events result in only changes in the expression level of genes, as has been suggested. 45, 46 Indeed, 229 different chromosomal bands are involved in 544 distinct recurrent unbalanced chromosomal abnormalities in human AML (see the National Cancer for Biotechnology Information, Cancer Genome Anatomy Project, Breakpoint Map of Recurrent Chromosome Aberrations: http://www.ncbi. nlm.nih.gov/CGAP/mitelsum.cgi). Southern blotting analysis and comparative genome hybridization are now revealing new chromosomal regions that are often amplified or deleted in AML. [48] [49] [50] MuLV mutagenesis has great appeal as an AML gene discovery tool, not only for generating candidates for alteration in human AML, but also for defining biochemical pathways important for AML in general. Recent advances in MuLV mutagenesis make this much more practical on a large scale.
Techniques for discovery of genes mutated by MuLV proviral insertion
The discovery of genes mutated by proviral insertion in MuLVinitiated AML has been slowed by the need to generate lambda libraries for each tumor studied in order to clone insertion sites. Indeed, subgenomic lambda libraries are often constructed for the purpose of cloning specific proviral/ cellular DNA junction fragments, without cloning endogenous ecotropic MuLV insertions. This general strategy is outlined in Figure 2 . This strategy is a very time consuming and expensive approach for the identification of common sites of proviral insertion; that is, a chromosomal region occupied by a provi- rus in multiple, independent tumors. A major assumption in studies of MuLV-induced leukemia is that proviral insertion is essentially random and that common sites are observed in tumor samples due to selection of rare cells with proviral insertions at these common sites. The selective pressure for survival and expansion of these rare cells into leukemic clones is provided by the effect of proviral insertion on the expression of a nearby cancer gene. In general, however, most newly cloned sites of proviral insertion cannot be shown to be common sites of proviral insertion. Due to this fact, various approaches have been taken to predict, prior to molecular cloning, which proviruses are likely to be at common sites of insertion. One approach has been to attempt to observe similar sized restriction enzyme fragments, detected on Southern blots using retroviral probes, from multiple tumor DNAs digested so as to generate proviral/cellular DNA junction fragments. 51 This approach is limited by the fact that, for multiple, different enzymes to yield bands of the same size, proviruses from different tumors must be integrated in a nearly identical place and in the same orientation in different tumors. Also, because most MuLV-induced tumors harbor multiple, somatically acquired proviral insertions, bands of similar size often cloud the picture. Another approach has been to identify rare Leukemia tumors with only one somatically acquired proviral insertion; the assumption being that the single insertion present must have mutated a cancer gene in order for oncogenesis to have ensued. Such tumors are very rare, however, and nonecotropic MuLV which are not detected with most probes commonly in use, can be present as clonal, tumor-specific integrants. 29, 52 Several powerful new approaches for rapidly identifying new candidate leukemia genes have been developed for BXH-2 strain AML. BXH-2 is one of 12 recombinant inbred strains developed by crossing C57BL/6J and C3H/HeJ mice. Unlike either parental strain or the other strains in this recombinant inbred strain series, more than 95% of BXH-2 mice will develop AML by 1 year of age. 16 A replication-competent, Becotropic MuLV arose during the systematic inbreeding of BXH-2, probably by recombination between defective endogenous MuLV in the C3H/HeJ and C57BL6/J strains. This B-ecotropic MuLV is now passed from mother to offspring in BXH-2 mice. Thus, all BXH-2 mice are viremic their entire lives, which results in AML development. 53 BXH-2 AML has been variably described as myeloblastic or myelomonocytic leukemia. 7, 16 On average, BXH-2 AML have three to four somatically acquired, clonal, tumor-specific proviral inser-
Figure 2
Cloning common sites of proviral insertion. Proviral/cellular DNA junction fragments are identified by Southern blotting using retrovirus-specific probes in the left-hand blot. Tumor DNAs (T 1 , T 2 , T 3 ) and normal DNA (C) contain three germline MuLV in this example which do not vary in size between samples. In addition to these germline proviruses, the tumor DNAs show multiple somatically acquired, clonal, tumor-specific proviruses. A junction fragment of interest is cloned (black box) and a probe flanking the site of proviral insertion is generated. This probe is used to detect proviral insertions at this locus in other AML. In this example, as shown in the right-hand blot, all three tumors show, in addition to the unrearranged or germline band, a band of a different size, indicating proviral insertion into one allele. Thus, a common site of proviral insertion is defined (ie a locus into which multiple, independent tumors have acquired a proviral insertion).
tions. 53 One very useful strategy, applied to BXH-2 AML to select for the proviral insertions most likely to affect the expression of nearby proto-oncogenes, has been to deliberately clone proviral insertions near CpG islands. 41 A survey of CpG island-associated restriction enzyme sites indicated that: SacII is frequently found within CpG islands; SacII infrequently cuts at non-CpG island sites; and SacII cuts once within most ecotropic MuLV genomes. 54, 55 Thus, SacII can be used as a surrogate marker for a CpG island. Proviral insertion near a CpG island will generate relatively small proviral/cellular DNA junction fragments, while those at a distance will generate large junction fragments not resolved by conventional agarose gels (Figure 3 ). Probes useful for detecting proviral insertions near genomic SacII sites that are 5Ј or 3Ј of the proviral SacII site are available (Figure 3) . In our experience, approximately 10-20% of randomly cloned BXH-2 AML proviral insertions can be later shown to be common sites of proviral insertion, while roughly 70-80% of proviruses cloned near SacII sites can be later shown to be common sites of proviral insertion (Ref. 41 , DAL unpublished observations).
The techniques described above can now be combined with more rapid PCR-based approaches to cloning proviral junction fragments. In particular, the use of long template, inverse PCR has made it practical to clone many more insertion sites in a shorter period of time than was previously possible (Ref. 43 , see comments in Ref. 56) . Furthermore, given the explosion in sequence data publicly available due to the expressed sequence tag, mouse and human genome projects, the generation of sequences from these clones is now very useful for establishing involved genes. It has been demonstrated previously that it is possible to amplify and clone proviral/cellular DNA junction fragments by inverse PCR; however, the size of the fragments that could be amplified limited the usefulness of the approach. 57, 58 Other approaches for rapid cloning of proviral insertions depend on modification of the MuLV genome prior to infection of susceptible mice.
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Figure 3
CpG island selection of proviral insertion sites. The top portion of the figure shows a proto-oncogene locus with an associated CpG island in the upstream region of the gene. Most CpG islands have SacII restriction enzyme sites. The lower portion of the figure shows proviral insertion into the promoter region, which may upregulate expression of the proto-oncogene. Proviral insertions near SacII sites can be detected as relatively small junction fragments using probes 1 and 2 shown. Probe 1 is called 5ЈEcoC and consists of a portion of the gag gene (DAL unpublished data). Probe 2 is the Akv5 probe described previously. 52 Proviruses not near a genomic SacII site will generate very large junction fragments not resolved on a typical agarose gel. The orientation of the provirus is indicated with an arrow.
The capacity to amplify large proviral/cellular DNA junction fragments has depended on new polymerase mixes with high processivity. In addition, the technique relies on careful choice of primers that are specific for ecotropic MuLV or that will amplify only a limited number of related MuLV in the mouse germline. The long, inverse PCR approach begins with digestion of AML genomic DNA with a restriction enzyme that generates proviral/cellular DNA junction fragments. The restriction enzyme is inactivated and the DNA is then diluted and ligated. Some of the junction fragments will undergo intramolecular ligation to create circular templates for PCR using carefully chosen retroviral primers with 3Ј ends oriented opposite to each other. After a second round of PCR using nested retroviral primers, the flanking genomic DNA is cloned into a plasmid vector (Figure 4) . We have developed primer pairs useful for amplifying junction fragments which extend 5Ј or 3Ј of the integrated proviruses in BXH-2 AML. These primer pairs work with all tested ecotropic MuLV (Ref. 43 , DAL unpublished observations). Junction fragments of up to11 kb have been amplified from BamHI, NcoI, and SacII digested AML genomic DNA.
A cancer gene Oort cloud: complexity in the genetics of MuLV-induced AML
Studies involving MuLV-initiated AML have now implicated a large number of cancer genes in myeloid leukemia (Table 2) . Moreover, it is clear that in some models, for example BXH-2 43 and Graffi-MuLV-induced AML, 60 a large number of different oncogenic events can contribute to AML. Indeed, if the number of loci is plotted against frequency of mutation in BXH-2 AML, a curve is generated like that in Figure 5 . The curve indicates that a large number of cancer genes exist that are mutated in a very small percentage of tumors and very few genes are mutated in high percentages of tumors. The situation is analogous to that of the Oort cloud, a large number of small icy objects surrounding our solar system whose total Long template, inverse PCR strategy for cloning sites of proviral insertion. Scheme for using long template, inverse PCR to clone proviral insertion sites. Total genomic DNA is digested with a restriction enzyme that creates a proviral/cellular DNA junction fragment (restriction enzyme X). Two rounds of PCR follow inactivation of the restriction enzyme and ligation. The secondary PCR product is cloned into a plasmid vector for further analysis (eg probe generation, sequencing).
Figure 5
The relationship between mutation frequency and gene number. The number of genes, which show a given frequency of proviral mutation in the BXH-2 AML model, is shown on the Y-axis and is plotted against frequency intervals on the X-axis. Few genes fall within the frequency intervals Ͼ4%. Specifically, insertions within the Nf1 gene at the Evi2 locus have been reported to occur in 15%, 51 in Cmyb in 8% (DAL unpublished observations), in Meis1 in 10%, 41, 85 and in Hoxa7 in 7% of BXH-2 AML. 41 More loci have been discovered with frequencies of mutation that fall within the 2-4% or 0-2% intervals. Specifically, Hoxa9 and Evi9 have been reported to be mutated in 2-4% 41 and several other loci (eg Evi27, Cdc25l) are now known to be involved in less than 2% of BXH-2 AML (DAL unpublished observations). The general curve described by these data is plotted.
size we can only estimate based on the number that occasionally drift into the inner solar system to appear as comets. Given the number of new AML genes we have seen in MuLVinduced models and the fact that most of them account for a relatively small number of cases, it may be true that a large
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Figure 6
Physiological roles of AML gene products in the cell. Genes affected at described common sites of proviral insertion from mouse models of AML are shown within a model cell. The gene products can be grouped by function and include receptors, proteins which regulate small G proteins, transcription factors and cell cycle regulators. In addition, several candidate AML genes that remain unclassified are indicated. number of relatively rare cancer genes exist. There are likely many genes, a veritable cancer gene Oort cloud, whose dysregulation can cause AML and which remain to be discovered. This plethora of cancer genes has several interesting implications from a genetic standpoint. First, many types of cancer may be characterized by a high degree of genetic complexity and may be highly evolved, with a large number of mutations that modify the survival, proliferation and spread of the selected clone. Second, the existence of so many cancer genes affords the opportunity to compare and classify them. For instance, it is possible that these genes could be grouped into informative classes, suggesting which biochemical pathways or processes are central to the AML phenotype. This process has begun in earnest in the BXH-2 model, owing to the large number of genes which have now been implicated. 43 A diagram of genes that are recurrently mutated by proviral insertion in MuLV-induced AML is shown in Figure 6 . It is clear that alterations in signal transduction, especially involving small GTPases, is one central theme of AML development in the mouse. Additionally, regulation of transcription factors important for lineage determination and differentiation, such as Evi1, Myb, Cbfa2 and the Hox genes, is highlighted. These attempts at classification can also reveal novel pathways that may be dysregulated in AML. For example, a gene encoding an actin binding protein (Clabp) and another involved in cholesterol metabolism (Hmgcr) have been implicated in BXH-2 AML. 43 Both genes may belong to pathways which so far have not been predicted a priori to be involved in AML development. Beyond the growing number of genes identified as likely targets at common sites of insertion in BXH-2 AML, inverse PCR resulted in the discovery of many genes that have so far been identified only at a single site of insertion. 43 Many of these 'single hit' genes are likely to have real roles in leukemogenesis, and indeed several are known oncogenes.
Another benefit of considering the large number of genes that can cause AML in mice is that it may be possible to define relationships between mutations that cause AML. At least three relationships could be imagined:
Figure 7
MuLV mutagenesis in genetically manipulated mice. (a) Mice carrying germline transgenes (or knockout alleles) which may confer a susceptibility to AML development can be crossed to BXH-2 (or another MuLV susceptible strain) to generate F1 mice. This can be followed by two or more backcrosses of the transgene to BXH-2 to generate transgene-positive and -negative littermates that are aged for AML development to ensue. The frequency and spectrum of mutations can be compared in AML developing in each class in an effort to define mutations that, in relation to the transgene, are redundant, neutral, or synergistic. (b) Proviral insertional mutagenesis of tumor suppressor loci using mice carrying chromosomal deletions. In this scheme, strain A, carrying a chromosomal deletion covering a tumor suppressor gene (TS), is crossed to strain B, which is susceptible to murine leukemia virus (MuLV)-induced leukemia. Resultant F1 animals, which carry the deletion, are backcrossed to strain B repeatedly to generate strain C mice which are MuLV susceptible and carry the chromosomal deletion. Strain C mice are infected with the MuLV, or in some strains are infected by viremic mothers, and aged. Tumor development is likely to involve loss of the single remaining wild-type TS allele in one of two ways: loss of the wild-type chromosome, accompanied by loss of heterozygosity (LOH), or proviral inactivation of the tumor suppressor gene. The latter case provides a molecular sequence tag for identification of the tumor suppressor gene.
Redundant: Mutation of one gene relieves pressure for selection of mutation of the redundant gene. Neutral: Mutation of one gene neither increases nor decreases pressure for selection of mutation in the neutral gene. Synergistic or Co-selected: Mutation of one gene results in strong pressure for selection of mutation in the synergistic gene.
The definition of such relationships is potentially very important. Redundant oncogenic events may exert their effects in a common pathway. Synergistic or co-selected mutations reveal critical points at which normal cellular regulation influences the ability of an oncogenic mutation to exert its effect. Thus, critical nodes for chemical intervention can be revealed. One excellent example of synergistic mutations in AML development was revealed by the observation that BXH-2 AML with Hoxa7 or Hoxa9 activating proviral insertions have also usually acquired activating proviral insertions at the Meis1 locus. 41 This strongly suggests that Hoxa7 or Hoxa9 can cooperate in leukemogenesis with Meis1. This hypothesis has been proven correct using retroviral transduction of primary hematopoietic stem cells, followed by transplantation into lethally irradiated recipient mice. Mice that received cells transduced with both Hoxa9 and Meis1 retroviruses rapidly developed AML, while those that received cells transduced with either retrovirus alone developed no AML or AML only after a long latent period. 61 Consistent with the possibility of similar synergy in humans, it has in fact been shown that HOXA9 and MEIS1 are often co-expressed in human AML. 62 The biochemical basis for this oncogenic cooperativity may lie in the fact that the HOXA9 cofactor, PBX1, requires MEIS1 for transport into the nucleus. 63 Others have demonstrated that a trimer of HOXA9, MEIS1 and PBX1 proteins can form on DNA. 64 It therefore seems likely that Hoxa/Meis1 synergy in leukemogenesis is a direct result of an intimate association in transcriptional regulation. Disruption of this association may have biological effects on AML which co-express these genes. These data reveal how determining the relationship between mutations (redundant, neutral, or synergistic) can suggest new avenues for understanding AML physiology.
One problem in distinguishing between redundant, neutral, and synergistic mutations is the fact that with few exceptions, common insertion sites in models like BXH-2 are involved in a very small subset of the tumors. This easily reduces any observed overlap or lack of overlap to statistical insignificance. Introducing one of the oncogenic changes into the germline of mice using mouse transgenesis provides a potential solution to this problem. In effect, this causes the 'first hit' to be present from birth. Transgenes or knockout mutations can then be bred to MuLV-susceptible mouse strains.
Several transgenes expressed in T or B cells have been bred on to, or generated in, MuLV susceptible strains and then infected with Moloney MuLV or another virus to accelerate lymphomagenesis. In this way, various collaborating oncogenes have been found for Cmyc in T and B cell lymphomagenesis. 65, 66 Similar studies should be possible in AML with the advent of promoters suitable for expression in the myeloid compartment.
Combining MuLV mutagenesis with engineered germline mutations
Several promoter constructs are now available which can express transgenes in some compartment of the early myeloid lineage. They include the human FMS and cathepsin G gene promoters, and the mouse Mrp8 and Tec gene promoters. 67, 70 These transgene constructs have been used to study the effect of Bcl2 overexpression in myeloid cells, 67 and to model AML M3, which is associated with expression of fusion oncoproteins involving the retinoic acid receptor alpha gene. 25, 26 It would be possible to cross potential oncogenes expressed from such transgenes on to an MuLV-susceptible strain such as the BXH-2 strain, by a limited number of backcrosses (Figure 7a ). The transgenic BXH-2 mice and their non-transgenic littermates could then be aged for AML development. The spectrum and incidence of oncogenic changes present in the transgenic and non-transgenic littermates could then be compared. Mutations that synergized would be expected to increase in frequency, while mutations that are redundant would be expected to decrease in frequency in transgenic BXH-2 AML. This same approach could be envisioned as a way to define redundant and synergistic oncogenic changes for fusion oncoproteins known to be involved in human AML. In these cases of human AML, secondary genetic events, while widely believed to be necessary for leukemogenesis, have not been defined. In similar experiments, tumor suppressor gene mutations could be introduced in mice using knockout technology and bred on to the BXH-2 strain background. This has been done for the Nf1 gene. 40 The result was that BXH-2-Nf1+/− mice developed AML faster than did BXH-2-Nf1+/+ littermates. Furthermore, these faster-developing BXH-2-Nf1+/− AML showed either loss of the wild-type Nf1 allele or proviral insertion into the Nf1 gene, which has been shown to inactivate it. 29 This result confirmed that proviral insertion into the Nf1 gene is functionally equivalent to loss of the Nf1 allele. This experiment also showed that it is possible to influence the genetic pathway favored during AML development in BXH-2 by germline modification. An extension of this type of experiment would be to create mice hemizygous for large chromosomal regions that cover regionally localized, but as yet not cloned, tumor suppressor genes, using embryonic stem cell technology. 71, 72 Such regions can be defined in the mouse based on conserved linkage homology between the mouse and human genomes. 73 These deletion chromosomes would then be crossed on to the BXH-2 strain. The resultant mice would be aged for AML development and the tumors screened for MuLV insertions in the region covered by the deletion on the wild-type chromosome homolog ( Figure  7b ). In this manner, it may be possible to use MuLV mutagenesis to identify myeloid tumor suppressor genes.
An integrated AML database and tumor repository
The new techniques for gene discovery in models of MuLVinitiated leukemia can make possible the correlation of genetic, biochemical, and phenotypic data in preserved banks of heterogeneous cancers (Figure 8) . A repository of MuLVinduced AML samples and associated insertion site data that is searchable via a web-based interface could make such a resource available to a broad array of scientists. Thus, different technologies could be brought to bear on a common set of tumor samples that has been genetically well characterized. In this way, the data would be cumulative and the benefit
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Figure 8
Utilizing an integrated AML database and repository. Systematic analysis of proviral insertion site data and generation of an associated AML repository is shown in this figure. Mice from the model in question are aged for tumor development. Each tumor is given a unique identifier and at least four resources are stored in the tumor repository: viable freezes of cells for subsequent passage in histocompatible mice, frozen tissue for RNA preparation, embedded tissue for histology, and genomic DNA for cloning sites of proviral insertion. The genomic DNA is subjected to long template, inverse PCR to clone as many sites of proviral insertion as possible. The sequences from insertion site clones are compared with a database of other cloned proviral insertion sites as well as by BLAST search against the non-redundant and EST databases maintained at the National Center for Biotechnology Information. Any clones that show sequence overlap with another insertion site clone are likely to be common. The likely availability of the entire human and mouse genome sequences within the next several years will make it possible to identify the closest known and putative genes for each insertion. This information can be correlated with the vast amount of cytogenetic data that have been generated for human AML. It is imagined that an integrated database would then be developed which associates each tumor with its proviral insertion sites. The database would also contain information about each AML's phenotype, as determined by histochemical and other methods. Hypotheses about the result of particular gene mutations could be tested using mRNA or viable freezes from the tumor repository. This information would accumulate upon the same set of AML samples and could be made public via a searchable website.
would multiply. Viable freezes of all these cancer samples, which could be passaged in histocompatible or immunocompromised mice at a later time, would provide a powerful resource for translational cancer studies. For instance, it may be possible to correlate genetic status with metastatic potential, response to specific therapies and other cancer phenotypes. Studies utilizing the hybridization of large gene arrays could allow for the correlation of gene expression patterns with specific mutations present in these tumors.
The simple question to be asked in the long term based on such studies is: if we understand the combination of most or all of the genetic changes that have occurred during the development of a tumor, then can we cure these cancers using a combination of rational, targeted therapies? Tests on a panel of tumors, each of which harbored one common mutation but differed in other ways, would more truly approximate the situation found in human cancers.
Conclusions
The MuLV-induced AML models now stand ready to make much larger contributions to our understanding of AML initiation, progression and maintenance. Recent advances in genomics and new technologies in cloning have dramatically shortened the gene discovery phase of the study of MuLVinduced AML. The plethora of AML genes implicated has raised several new hypotheses regarding AML development. For example, signaling through small GTPase proteins, Ras as well as others, is likely to be of major importance for abnormal myeloid cell growth. Guanine nucleotide exchange factor genes have been implicated as candidates for human myeloid leukemia. The studies have also helped bolster the concept that dysrgeulation of homeotic genes may contribute to leukemia and that many leukemic fusion oncoproteins may operate upon HOX and MEIS transcription factors in regulating cell differentiation and growth. It is likely that new techniques in germline modification of mice will synergize with MuLV mutageneis for the study of relationships between oncogenic mutations and for the discovery of cooperating oncogenes for clinically important fusion oncoproteins. It is a worthwhile goal to develop more comprehensive programs of MuLVinduced AML research because they can make possible extensive correlation of genetic, biochemical, and phenotypic data for large banks of AML samples.
